INVESTOR ALERT: Levi & Korsinsky, LLP Announces Investigation Of Covidien Plc And Its Board Of Directors In Connection With The Sale Of The Company To Medtronic, Inc. --COV

Levi & Korsinsky is investigating the Board of Directors of Covidien plc (“Covidien” or “the Company”) (NYSE:COV) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Medtronic, Inc. (“Medtronic”) (NYSE:MDT).

Click here to learn more about the investigation:, or call: 877-363-5972. There is no cost or obligation to you.

Under the terms of the transaction, Covidien shareholders will receive $35.19 in cash and 0.956 shares of Medtronic for each share of Covidien stock they own, representing an approximate value of $93.22 per Covidien share. The investigation concerns whether the Covidien Board of Directors breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into this transaction, and whether Medtronic is underpaying for Covidien shares.

If you own Covidien common stock and wish to obtain additional information, please contact Joseph E. Levi, Esq. either via email at or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit

Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm’s 26 attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.

Copyright Business Wire 2010

If you liked this article you might like

Jim Cramer -- Deal Activity in Specialty Pharma Reaches a Frenzied Pace

Mallinckrodt Buys Ikaria in $2.3 Billion Hospital Treatment Deal

Stryker and Smith & Nephew Are the Stars to Watch in Medtech's 2015 Merger Dance

Medtronic Avoids U.S. Taxes While Saddling Shareholders With a Hefty Tax Bill

Trim Positions in Stryker Ahead of Fourth-Quarter Earnings; Buy on Pullback